Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib
-
Published:2021-01-03
Issue:8
Volume:100
Page:2005-2014
-
ISSN:0939-5555
-
Container-title:Annals of Hematology
-
language:en
-
Short-container-title:Ann Hematol
Author:
Caocci GiovanniORCID, Mulas Olga, Capodanno Isabella, Bonifacio Massimiliano, Annunziata Mario, Galimberti Sara, Luciano Luigiana, Tiribelli Mario, Martino Bruno, Castagnetti Fausto, Binotto Gianni, Pregno Patrizia, Stagno Fabio, Abruzzese Elisabetta, Bocchia Monica, Gozzini Antonella, Albano Francesco, Fozza Claudio, Luzi Debora, Efficace Fabio, Simula Maria Pina, Scaffidi Luigi, Baratè Claudia, De Gregorio Fiorenza, Stella Rossella, Gugliotta Gabriele, Pirillo Francesca, Trawinska Malgorzata Monika, Sicuranza Anna, Cattaneo Daniele, Attolico Immacolata, Scalzulli Emilia, Iurlo Alessandra, Foà Robin, Breccia Massimo, La Nasa Giorgio
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference31 articles.
1. Sacha T, Saglio G (2019) Nilotinib in the treatment of chronic myeloid leukemia. Future Oncol 15(9):953–965 2. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim D-W, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 30(5):1044–1054 3. Aghel N, Lipton JH, Atenafu EG, Kim DDH, Delgado DH (2017) Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long-term follow-up. Clin Lymphoma Myeloma Leuk 17(12):870–878.e1 4. Bondon-Guitton E, Combret S, Pérault-Pochat MC, Stève-Dumont M, Bagheri H, Huguet F, Despas F, Pathak A, Montastruc JL (2016) Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy. Target Oncol 11(4):549–552 5. Caocci G, Mulas O, Annunziata M, Luciano L, Bonifacio M, Orlandi EM, Pregno P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N, Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F, Efficace F, Usala E, de Gregorio F, Scaffidi L, Elena C, Pirillo F, Baratè C, Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, la Nasa G, Foà R, Breccia M (2018) Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: identification of risk factors and the role of prophylaxis. Am J Hematol 93(7):E159–E161
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|